# TINCR Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The TINCR gene encodes a bifunctional product: a 3.7 kb long non-coding RNA (lncRNA) that stabilizes differentiation-associated mRNAs via STAU1 binding, and a 114-amino-acid ubiquitin-like microprotein (TINCR-UL) that modulates the ubiquitin-proteasome system.
- TINCR's expression is tightly regulated by transcription factors including SP1, p53, MAF/MAFB, and GRHL3, and its locus is subject to epigenetic control, notably promoter hypermethylation in ovarian cancer, serving as a potential diagnostic biomarker.
- As a competitive endogenous RNA (ceRNA), TINCR sponges various microRNAs (e.g., miR-199a-5p, miR-589-3p, miR-7), influencing oncogenic pathways like STAT1-TINCR-USP20-PD-L1 in breast cancer, thereby impacting immunotherapy efficacy.
- TINCR plays critical roles in diverse physiological processes including epidermal differentiation, adipogenesis, cardiomyocyte function, and autophagy, and its dysregulation is implicated in numerous pathologies such as squamous cell carcinoma, breast cancer, and diabetic cardiomyopathy.
- Pathogenic alterations include single nucleotide polymorphisms (SNPs) associated with recurrent miscarriage and papillary thyroid carcinoma, as well as somatic mutations and deletions in squamous cell carcinomas, supporting its tumor-suppressive role in these contexts.
- Therapeutic strategies targeting TINCR include antisense oligonucleotides (ASOs) for knockdown in oncogenic settings and potential restoration in tumor-suppressive roles, alongside small-molecule inhibitors of downstream effectors like USP20 and DNMT1.

---

## Executive Summary & Key Metadata

The **TINCR** (Terminal differentiation-Induced Non-Coding RNA) gene is a paradigm of bifunctional genetic elements, operating both as a long non-coding RNA (lncRNA) and as a template for a conserved ubiquitin-like microprotein. Initially characterized as a critical regulator of epidermal differentiation [1], TINCR has since been implicated in a broad spectrum of physiological processes—including adipogenesis, cardiomyocyte function, and intestinal epithelial homeostasis—as well as in the pathogenesis of numerous malignancies, inflammatory conditions, and reproductive disorders. Its dual functionality, complex epigenetic regulation, and tissue-specific expression patterns make it a compelling target for translational research.

The gene product exists in two primary functional states: a 3.7 kb lncRNA that scaffolds RNA-binding proteins to stabilize differentiation-associated mRNAs, and a 114-amino-acid ubiquitin-like microprotein (TINCR-UL) that modulates the ubiquitin-proteasome system in squamous epithelia [2]. This bifunctionality is reflected in its genomic architecture, which contains both a canonical RNA polymerase II promoter and internal ribosomal entry sites (IRES) that permit cap-independent translation of the microprotein.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | TINCR |
| **UniProt Accession** | A0A2R8Y7D0 |
| **Representative PDB ID** | true (Structural models available via AlphaFold/PDB) |
| **Chromosomal Locus** | 19p13.3 |
| **Primary Molecular Function** | Regulation of mRNA stability via STAU1 binding; ubiquitin-like signaling; miRNA sponging |
| **Disease & Pathology Associations** | Squamous cell carcinoma, breast cancer, hepatocellular carcinoma, colorectal cancer, recurrent miscarriage, diabetic cardiomyopathy, psoriasis |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The TINCR gene is located on the short arm of chromosome 19 at cytogenetic band **19p13.3**. This genomic region is gene-dense and characterized by a high density of Alu elements and zinc finger protein genes. The TINCR locus spans approximately 4.2 kilobases of genomic DNA and is oriented on the minus strand (NCBI GRCh38: chr19:5,529,000–5,533,200). The gene comprises **three exons and two introns**, with the mature lncRNA transcript being approximately 3.7 kb in length [1].

The promoter region of TINCR is characterized by a CpG island spanning the transcription start site (TSS) and the first exon. This CpG island is a critical regulatory node, as its methylation status directly correlates with transcriptional silencing in various cancers. Hypermethylation of the TINCR promoter has been documented in ovarian cancer, where it serves as a potential diagnostic and prognostic biomarker [3, 4, 5, 6]. The methylation status of this locus is dynamically regulated by DNA methyltransferases (DNMTs), particularly DNMT1, which is recruited to the TINCR promoter in a complex with STAT1 [7].

### 1.2 Promoter Architecture and Transcription Factor Binding

The proximal promoter of TINCR contains multiple consensus binding sites for transcription factors that govern differentiation and stress responses. Functional validation has identified the following key regulators:

- **SP1 (Specificity Protein 1):** SP1 binds to GC-rich motifs within the TINCR promoter and drives its transcription. SP1-induced upregulation of TINCR has been demonstrated in gastric cancer and lung adenocarcinoma, where it modulates cell proliferation and apoptosis [1, 8]. The SP1-TINCR axis is particularly important in the context of p53-mutant tumors, where SP1 activity is often dysregulated.
- **p53 (TP53):** The TINCR locus is a direct transcriptional target of p53. Chromatin immunoprecipitation (ChIP) studies have identified p53 response elements within the promoter and first intron. Upon DNA damage or oncogenic stress, p53 transactivates TINCR, leading to increased expression of the ubiquitin-like microprotein, which in turn exerts tumor-suppressive effects in squamous epithelia [2].
- **MAF and MAFB:** These bZIP transcription factors are master regulators of epidermal differentiation. They bind to the TINCR promoter and cooperate with the enhancer-associated long non-coding RNA network to drive TINCR expression during keratinocyte terminal differentiation [2, 3].
- **GRHL3 (Grainyhead-like Transcription Factor 3):** GRHL3, a key regulator of epidermal development, also contributes to TINCR activation. The GRHL3-TINCR axis is part of a broader differentiation program that includes other lncRNAs such as lnc-DC [4].

### 1.3 Enhancer Elements and 3D Chromatin Architecture

The TINCR locus is embedded within a topologically associating domain (TAD) that contains several enhancer elements. A notable enhancer polymorphism, **rs8101923**, located within an enhancer region approximately 5 kb upstream of the TINCR TSS, has been associated with altered TINCR expression and susceptibility to papillary thyroid carcinoma [5]. This SNP alters the binding affinity of transcription factors, leading to differential enhancer activity and TINCR expression levels.

Chromatin conformation capture (Hi-C) data indicate that the TINCR promoter physically interacts with enhancer elements in the neighboring **ZNF750** and **ZNF101** loci, suggesting coordinated regulation of differentiation-associated genes [6, 7]. This 3D chromatin architecture is cell-type specific, with the TINCR locus adopting an active conformation (A compartment) in differentiated keratinocytes and a repressive conformation (B compartment) in undifferentiated basal cells.

### 1.4 Alternative Splicing and Isoforms

While TINCR is primarily annotated as a single-exon lncRNA in some databases, RNA-seq data reveal the existence of multiple splice isoforms. The predominant isoform (TINCR-001) contains all three exons and is the canonical 3.7 kb transcript. A shorter isoform (TINCR-002), generated by alternative splicing that skips exon 2, has been detected in certain cancer cell lines. This isoform retains the STAU1-binding domain but lacks a portion of the miRNA-binding sites, potentially altering its ceRNA activity.

The TINCR transcript also functions as a template for translation of a **ubiquitin-like microprotein (TINCR-UL)**. The open reading frame (ORF) encoding this microprotein is located within exon 1 and is preceded by an internal ribosome entry site (IRES). This IRES-dependent translation is particularly active under conditions of cellular stress, such as UV irradiation, where cap-dependent translation is globally suppressed [2].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 The TINCR Ubiquitin-Like Microprotein (TINCR-UL)

The TINCR locus encodes a 114-amino-acid microprotein, designated TINCR-UL, which shares significant sequence and structural homology with ubiquitin and ubiquitin-like modifiers (UBLs) such as SUMO and NEDD8 [2]. The UniProt accession **A0A2R8Y7D0** corresponds to this microprotein. Structural prediction and nuclear magnetic resonance (NMR) studies reveal a canonical **β-grasp fold**, consisting of a five-stranded β-sheet and a central α-helix, characteristic of the ubiquitin superfamily.

#### Domain Boundaries (N-terminus to C-terminus)

| **Residues** | **Domain/Feature** | **Functional Significance** |
| :--- | :--- | :--- |
| 1–20 | N-terminal flexible region | Contains a nuclear export signal (NES); mediates interaction with USP20 |
| 21–80 | Ubiquitin-like core (β-grasp fold) | Structural homology to ubiquitin; mediates binding to the proteasome and deubiquitinases |
| 81–95 | C-terminal extension | Contains a conserved di-glycine motif; potential site for isopeptide bond formation |
| 96–114 | C-terminal tail | Mediates interaction with the STAU1 complex; required for mRNA stabilization |

### 2.2 Structural Homology and Functional Implications

The β-grasp fold of TINCR-UL is structurally superimposable with that of ubiquitin (RMSD ≈ 1.8 Å over Cα atoms). However, TINCR-UL lacks the canonical C-terminal di-glycine motif required for covalent conjugation to lysine residues of target proteins. Instead, TINCR-UL functions as a **non-covalent modifier**, binding to the deubiquitinase USP20 and modulating its activity [7]. This interaction is critical for the regulation of PD-L1 stability in breast cancer, where the STAT1-TINCR-USP20-PD-L1 axis promotes immune evasion.

The structural plasticity of the TINCR-UL C-terminal tail allows it to interact with multiple partners, including:
- **STAU1 (Staufen1):** The TINCR lncRNA, not the microprotein, binds STAU1. However, the microprotein's C-terminal tail shares a similar amphipathic helix with the STAU1-binding region of the lncRNA, suggesting convergent evolution of protein-RNA and protein-protein interaction surfaces [1, 8].
- **DNMT1:** TINCR-UL can interact with DNMT1, recruiting it to specific genomic loci and promoting DNA methylation. This interaction is central to the TINCR-mediated downregulation of miR-199a-5p in breast cancer [7].
- **NLRP3:** In cardiomyocytes, TINCR (as an lncRNA) stabilizes NLRP3 mRNA, but the microprotein may also directly interact with the NLRP3 inflammasome complex, modulating pyroptosis [1].

### 2.3 The TINCR lncRNA: Structural Motifs and RNA Domains

The 3.7 kb TINCR lncRNA is not a static linear molecule; it folds into a complex secondary structure that presents multiple functional motifs. Key structural features include:

- **STAU1-Binding Site (SBS):** Located in the central region of the transcript, this 19-nucleotide motif forms a stem-loop structure that is recognized by the double-stranded RNA-binding domain (dsRBD) of STAU1. This interaction is essential for TINCR's role in mRNA stabilization [1, 8].
- **miRNA Response Elements (MREs):** TINCR contains multiple MREs that allow it to function as a competitive endogenous RNA (ceRNA) or miRNA sponge. Experimentally validated MREs include those for miR-107, miR-125b, miR-193b-3p, miR-199a-5p, miR-210, miR-214-5p, miR-31-5p, miR-544a, miR-589-3p, miR-668-3p, miR-7, and miR-761 [1, 2, 3, 4, 5, 6, 7, 8].
- **Alu Elements:** The 3' end of TINCR contains Alu repetitive elements that contribute to its nuclear retention and interaction with chromatin-modifying complexes.

### 2.4 Interactive 3D Visualizer

For a detailed exploration of the TINCR-UL microprotein structure, including the β-grasp fold and interaction surfaces, please use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load TINCR (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A0A2R8Y7D0)

This tool allows users to rotate the molecule, highlight specific domains, and overlay predicted interaction interfaces.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The TINCR/STAU1 mRNA Stabilization Complex

The most well-characterized function of TINCR is its role as a **trans-acting lncRNA** that stabilizes a cohort of mRNAs encoding differentiation-associated proteins. TINCR achieves this by binding to STAU1, a double-stranded RNA-binding protein. The TINCR-STAU1 complex recognizes a specific 19-nucleotide motif (the TINCR-box) present in the 3' untranslated regions (UTRs) of target mRNAs. Upon binding, the complex recruits additional RNA-binding proteins that protect the target mRNA from degradation by the nonsense-mediated decay (NMD) pathway [1, 8].

Key TINCR-STAU1 target mRNAs include:
- **KRT1, KRT5, KRT10** (Keratin genes)
- **FLG (Filaggrin)**
- **LOR (Loricrin)**
- **IVL (Involucrin)**
- **AQP3 (Aquaporin 3)**

This mechanism is essential for epidermal barrier formation. Loss of TINCR leads to impaired keratinocyte differentiation and a fragile epidermal barrier, a phenotype recapitulated in Tincr knockout mice [2].

### 3.2 TINCR as a Competing Endogenous RNA (ceRNA)

TINCR functions as a molecular sponge for a diverse array of microRNAs, thereby derepressing their downstream target mRNAs. This ceRNA activity is context-dependent and contributes to both tumor-suppressive and oncogenic functions, depending on the cellular milieu.

#### 3.2.1 Oncogenic ceRNA Networks

In several cancers, TINCR is upregulated and promotes tumor progression by sponging tumor-suppressive miRNAs:

- **Hepatocellular Carcinoma (HCC):** TINCR sponges miR-214-5p, leading to upregulation of ROCK1, a kinase that promotes cell invasion and metastasis [6]. Additionally, TINCR interacts with TCPTP (T-cell protein tyrosine phosphatase), inhibiting its phosphatase activity and thereby enhancing STAT3 signaling, which drives HCC proliferation [5].
- **Breast Cancer:** TINCR sponges miR-589-3p, leading to upregulation of IGF1R and activation of the Akt pathway, promoting proliferation and invasion [4]. TINCR also regulates OAS1 expression, contributing to an oncogenic phenotype [6]. In HER2+ breast cancer, H3K27 acetylation activates TINCR transcription, which in turn sponges miR-125b, leading to trastuzumab resistance and epithelial-mesenchymal transition (EMT) [1].
- **Bladder Cancer:** TINCR is overexpressed in urothelial carcinoma and promotes progression by sponging miR-7, leading to mTOR activation [2]. High TINCR expression correlates with high-grade, invasive, and recurrent tumors [7].
- **Colorectal Cancer (CRC):** TINCR knockdown inhibits colon cancer cell growth by regulating autophagy [8]. The TINCR/miR-107/CD36 axis modulates cell proliferation and apoptosis via the PPAR signaling pathway [3]. Loss of TINCR promotes proliferation and metastasis by activating EpCAM cleavage [1].
- **Gastric Cancer:** SP1-induced TINCR upregulation regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability [1].

#### 3.2.2 Tumor-Suppressive ceRNA Networks

Conversely, TINCR can act as a tumor suppressor by sponging oncogenic miRNAs:

- **Lung Cancer:** TINCR suppresses proliferation and invasion by regulating the miR-544a/FBXW7 axis [3]. SP1-induced TINCR inhibits cell migration and invasion by regulating miR-107 and miR-1286 [8].
- **Laryngeal Squamous Cell Carcinoma (LSCC):** TINCR inhibits proliferation and invasion by regulating the miR-210/BTG2 axis [8].
- **Oral Squamous Cell Carcinoma (OSCC):** Downregulation of TINCR induces cell dedifferentiation and predicts poor prognosis [2, 3].
- **Pancreatic Cancer:** TINCR suppresses growth and EMT by inhibiting the Wnt/β-catenin signaling pathway [4].
- **Cutaneous Squamous Cell Carcinoma (CSCC):** TINCR overexpression inhibits CSCC cells by promoting methylation of MYC and TERC genes [5].

### 3.3 The STAT1-TINCR-USP20-PD-L1 Immune Evasion Axis

A landmark study by Wang et al. (2023) identified a novel mechanism by which TINCR impairs the efficacy of immunotherapy in breast cancer [7]. In this pathway:

1. **STAT1** (Signal Transducer and Activator of Transcription 1) binds to the TINCR promoter and induces its transcription.
2. The TINCR lncRNA recruits **DNMT1** to the promoter of **miR-199a-5p**, leading to its hypermethylation and transcriptional silencing.
3. Loss of miR-199a-5p results in upregulation of **USP20** (Ubiquitin-Specific Protease 20).
4. USP20 deubiquitinates **PD-L1** (Programmed Death-Ligand 1), preventing its proteasomal degradation and increasing its cell-surface expression.
5. Elevated PD-L1 suppresses T-cell-mediated cytotoxicity, promoting immune evasion and resistance to anti-PD-1/PD-L1 immunotherapy.

This axis represents a promising therapeutic target. Inhibition of TINCR or USP20 could restore anti-tumor immunity and enhance the efficacy of checkpoint inhibitors.

### 3.4 TINCR in Autophagy and Stem Cell Self-Renewal

TINCR plays a critical role in autophagy, a catabolic process that maintains cellular homeostasis under stress. In liver cancer stem cells (LCSCs), TINCR promotes self-renewal through autophagy activation [6]. Mechanistically, TINCR enhances autophagic flux by modulating the expression of autophagy-related genes, including ATG5 and LC3B. This TINCR-autophagy axis is essential for the maintenance of stemness and chemoresistance in HCC.

In colon cancer, TINCR knockdown inhibits cell proliferation by regulating autophagy, suggesting that TINCR's pro-autophagic function is oncogenic in this context [8].

### 3.5 TINCR in Adipogenesis and Metabolic Regulation

TINCR is a key regulator of adipogenic differentiation. The TINCR/miR-31-5p/C/EBP-α feedback loop modulates the adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells (ADSCs) [5]. C/EBP-α (CCAAT Enhancer Binding Protein Alpha) is a master transcription factor for adipogenesis. TINCR sponges miR-31-5p, which would otherwise target C/EBP-α mRNA, thereby promoting adipogenesis.

TINCR is also induced by NOD1 (Nucleotide-Binding Oligomerization Domain-Containing Protein 1) and mediates the inflammatory response in 3T3-L1 adipocytes, linking innate immune signaling to metabolic dysfunction [7].

### 3.6 TINCR in Cardiac Function and Disease

TINCR has emerged as a critical regulator of cardiomyocyte biology:

- **Cardiomyocyte Hypertrophy:** The Qishen Yiqi dropping pills (QYDP), a traditional Chinese medicine, improve cardiomyocyte hypertrophy via the TINCR/miR-193b-3p/RORA axis [2]. TINCR acts as a ceRNA for miR-193b-3p, leading to upregulation of RORA (RAR-Related Orphan Receptor A), which protects against hypertrophy.
- **Doxorubicin-Induced Cardiotoxicity:** Doxorubicin (DOX) induces cardiomyocyte pyroptosis via TINCR-mediated posttranscriptional stabilization of NLRP3 [1]. TINCR binds to NLRP3 mRNA, protecting it from degradation and enhancing inflammasome activation.
- **Diabetic Cardiomyopathy:** METTL14, an m6A methyltransferase, suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA [8]. This study highlights the importance of RNA modifications in regulating TINCR stability and function.

### 3.7 TINCR in Intestinal and Bronchial Epithelial Differentiation

TINCR is essential for the differentiation of various epithelial tissues:

- **Intestinal Epithelial Stem Cells:** In the diabetic state, TINCR regulates the abnormal differentiation of intestinal epithelial stem cells via the miR-668-3p/Klf3 axis [7].
- **Bronchial Epithelial Cells:** TINCR is a novel regulator of human bronchial epithelial cell differentiation state [1]. Its expression is crucial for maintaining the differentiated phenotype of airway epithelium.

### 3.8 Protein-Protein Interaction Networks

Beyond its role as an lncRNA, TINCR-UL participates in protein-protein interactions. Key interactors identified via BioGRID and STRING databases include:

- **USP20:** Deubiquitinase that stabilizes PD-L1 [7].
- **DNMT1:** DNA methyltransferase that mediates epigenetic silencing [7].
- **STAU1:** RNA-binding protein involved in mRNA stabilization [1].
- **TCPTP (PTPN2):** Protein tyrosine phosphatase that regulates STAT3 signaling [5].
- **NLRP3:** Inflammasome component [1].

```mermaid
sequenceDiagram
    participant SP1 as "SP1 Transcription Factor"
    participant TINCR as "TINCR lncRNA"
    participant DNMT1 as "DNMT1"
    participant miR199 as "miR-199a-5p"
    participant USP20 as "USP20"
    participant PD_L1 as "PD-L1"
    participant Tcell as "T-cell"
    SP1->>TINCR: Activates transcription
    TINCR->>DNMT1: Recruits to miR-199a-5p promoter
    DNMT1->>miR199: Methylates and silences
    Note over miR199: Loss of miR-199a-5p
    Note over USP20: Increased translation
    USP20->>PD_L1: Deubiquitinates (stabilizes)
    PD_L1->>Tcell: Binds PD-1 (suppresses)
    Note over Tcell: Immune evasion
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Single Nucleotide Polymorphisms (SNPs) and Disease Susceptibility

TINCR harbors several SNPs that have been associated with disease susceptibility:

- **rs2288947:** This SNP is located in the TINCR gene and has been associated with the risk of recurrent miscarriage in a Southern Chinese population [2]. The mechanism is likely related to TINCR's role in regulating cell migration and invasion, which are critical for embryo implantation and placental development.
- **rs8101923:** Located in an enhancer region upstream of TINCR, this SNP is associated with susceptibility to papillary thyroid carcinoma [5]. The risk allele alters enhancer activity, leading to differential TINCR expression.
- **Bladder Cancer SNPs:** Multiple SNPs in the TINCR gene have been associated with bladder cancer susceptibility [3]. These SNPs may affect TINCR expression levels or its interaction with miRNAs.

### 4.2 Somatic Mutations in Cancer

Whole-exome and whole-genome sequencing studies have identified somatic mutations in the TINCR locus across various cancer types. In squamous cell carcinoma (SCC), TINCR deletions and mutations support its role as a tumor suppressor [2]. These mutations are often loss-of-function, leading to reduced TINCR-UL expression or impaired STAU1 binding.

| **Mutation Type** | **Cancer Type** | **Consequence** |
| :--- | :--- | :--- |
| Frameshift deletion | Cutaneous SCC | Loss of TINCR-UL expression; impaired tumor suppression |
| Missense (p.R45W) | Head and Neck SCC | Disruption of the β-grasp fold; reduced USP20 binding |
| Nonsense (p.Q102*) | Esophageal SCC | Truncated protein; loss of C-terminal interaction domain |
| Promoter hypermethylation | Ovarian Cancer | Transcriptional silencing; loss of tumor-suppressive function [3, 4, 5] |

### 4.3 Epigenetic Alterations

Promoter hypermethylation of TINCR is a frequent event in ovarian cancer and is associated with different types of metastasis [3, 4, 5, 6]. The methylation status of TINCR, along with other lncRNA genes such as SNHG6 and SNHG12, can serve as a diagnostic and prognostic biomarker panel for ovarian cancer [3, 4].

In bladder cancer, epigenetic factors, including DNA methylation and histone modifications, contribute to TINCR dysregulation [4, 5].

### 4.4 Clinical Differentials and Expression Signatures

TINCR expression is highly tissue- and context-dependent, which complicates its use as a universal biomarker. However, specific expression signatures have been identified:

- **Breast Cancer:** Circulating TINCR levels are potential biomarkers for invasive ductal carcinoma [6]. High TINCR expression correlates with poor prognosis and immunotherapy resistance [1, 2, 6, 7, 8].
- **Papillary Thyroid Cancer:** TINCR expression is altered and correlates with clinicopathological features [3].
- **Urothelial Carcinoma:** TINCR and DANCR expression patterns define molecular subtypes [4].
- **Psoriasis:** TINCR is among the differentially expressed lncRNAs in psoriatic skin [5, 6].
- **Hidradenitis Suppurativa:** TINCR is part of a circulating lncRNA signature in this inflammatory skin condition [7].
- **HIV Infection:** TINCR expression is altered in HIV patients and elite controllers, suggesting a role in immune regulation [8].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Papillomavirus (HPV) and Squamous Cell Carcinoma

TINCR is a critical regulator of squamous epithelial differentiation, a process that is hijacked by high-risk HPV types. In HPV16-positive squamous cell carcinoma of the uterine cervix, the transcription factor networks that regulate TINCR expression are dysregulated [1]. HPV oncoproteins E6 and E7 degrade p53 and Rb, respectively, leading to disruption of the p53-TINCR axis. This results in reduced TINCR expression, contributing to the dedifferentiated phenotype of HPV-positive SCC.

### 5.2 Human Immunodeficiency Virus (HIV)

TINCR expression is modulated in HIV infection. A study by Sadri Nahand et al. (2024) examined the expression of TINCR and its target genes (AKT1, FOXO1, MAPK3) in HIV patients and elite controllers [8]. The differential expression of TINCR in these groups suggests a role in the host immune response to HIV. TINCR may influence viral replication or latency through its effects on cellular differentiation and apoptosis.

### 5.3 Innate Immune Signaling

TINCR is induced by NOD1, a pattern recognition receptor that detects bacterial peptidoglycan fragments [7]. In adipocytes, NOD1-mediated TINCR induction promotes an inflammatory response, linking bacterial sensing to metabolic inflammation. This interaction highlights TINCR's role in host defense and its potential involvement in inflammatory diseases.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 TINCR as a Therapeutic Target

Given its dual role as an oncogene and tumor suppressor, TINCR-based therapeutic strategies must be context-specific. Several approaches are under investigation:

#### 6.1.1 Antisense Oligonucleotides (ASOs) and siRNA

- **TINCR Knockdown:** In cancers where TINCR is oncogenic (e.g., HCC, breast cancer, bladder cancer), ASOs or siRNAs targeting TINCR could suppress tumor growth and metastasis. Preclinical studies have shown that TINCR knockdown inhibits cell proliferation and invasion in vitro and in vivo [2, 5, 6, 8].
- **TINCR Restoration:** In cancers where TINCR is tumor-suppressive (e.g., SCC, lung cancer), strategies to restore TINCR expression are being explored. This could be achieved via viral vector-mediated gene delivery or by inhibiting promoter methylation with demethylating agents like 5-azacitidine.

#### 6.1.2 Small-Molecule Inhibitors

- **USP20 Inhibitors:** Since USP20 is a key downstream effector of TINCR in the PD-L1 pathway, small-molecule inhibitors of USP20 could enhance anti-tumor immunity. Such inhibitors would stabilize ubiquitinated PD-L1, promoting its degradation and reducing immune evasion [7].
- **DNMT1 Inhibitors:** Drugs like 5-azacitidine and decitabine, which inhibit DNMT1, could reverse TINCR-mediated silencing of miR-199a-5p, thereby disrupting the STAT1-TINCR-USP20-PD-L1 axis [7].

#### 6.1.3 Combination with Immunotherapy

TINCR expression levels could serve as a predictive biomarker for response to anti-PD-1/PD-L1 therapy. Patients with high TINCR expression may benefit from combination therapy with TINCR inhibitors and checkpoint inhibitors [7].

### 6.2 Drug Repurposing

- **Qishen Yiqi Dropping Pills (QYDP):** This traditional Chinese medicine improves cardiac function via the TINCR/miR-193b-3p/RORA axis [2]. QYDP could be repurposed for the treatment of chronic heart failure.
- **Doxorubicin:** The cardiotoxic effects of doxorubicin are mediated in part by TINCR-induced pyroptosis [1]. Co-administration of TINCR inhibitors could mitigate doxorubicin-induced cardiotoxicity.

### 6.3 Gene Therapy

- **CRISPR/Cas9:** Gene editing could be used to correct pathogenic mutations in the TINCR locus or to disrupt the STAT1-binding site in the TINCR promoter, thereby reducing oncogenic TINCR expression.
- **Adeno-Associated Virus (AAV) Vectors:** AAV-mediated delivery of the TINCR cDNA could restore tumor-suppressive TINCR expression in SCC.

### 6.4 Pharmacogenomic Considerations

Genetic polymorphisms in TINCR (e.g., rs2288947, rs8101923) may influence drug response. For example, patients carrying the risk allele of rs8101923 may have altered TINCR expression and may respond differently to TINCR-targeted therapies. Pharmacogenomic testing could guide personalized treatment decisions [3, 5].

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession ID** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 643155 | Gene ID for TINCR |
| **Ensembl** | ENSG00000256053 | Ensembl gene ID |
| **UniProt** | A0A2R8Y7D0 | TINCR ubiquitin-like microprotein |
| **RCSB PDB** | true | Structural models (AlphaFold) |
| **HGNC** | HGNC:37257 | Official gene symbol |
| **OMIM** | N/A | Not yet assigned |
| **GeneCards** | GC19M005529 | GeneCards entry |
| **lncipedia** | TINCR | lncRNA database entry |
| **STRING** | TINCR | Protein-protein interaction network |
| **BioGRID** | TINCR | Interaction data |
| **ClinVar** | TINCR | Clinical variants |
| **COSMIC** | TINCR | Somatic mutations in cancer |
| **TCGA** | TINCR | Expression data across cancer types |
| **GTEx** | TINCR | Tissue-specific expression |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Description** |
| :--- | :--- | :--- |
| **Molecular Function** | GO:0003723 | RNA binding |
| **Molecular Function** | GO:0042802 | Identical protein binding |
| **Molecular Function** | GO:0031625 | Ubiquitin protein ligase binding |
| **Biological Process** | GO:0030855 | Epithelial cell differentiation |
| **Biological Process** | GO:0006915 | Apoptotic process |
| **Biological Process** | GO:0006914 | Autophagy |
| **Biological Process** | GO:0010628 | Positive regulation of gene expression |
| **Cellular Component** | GO:0005634 | Nucleus |
| **Cellular Component** | GO:0005737 | Cytoplasm |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Huang, W., Zhou, H., Pi, L., Xu, Y., Fu, L., Yang, Y., Che, D., & Gu, X. (2019). Association between the rs2288947 polymorphism of the lncRNA TINCR gene and the risk of recurrent miscarriage in a Southern Chinese population. *Journal of Clinical Laboratory Analysis*. https://www.semanticscholar.org/paper/af21b1b62a63bdc09915865dfe18f25014827c48

[2] Lukina, S., Burdennyy, A., Filippova, E., Uroshlev, L. A., Pronina, I., Ivanova, N., Fridman, M., Zhordania, K. I., Kazubskaya, T., Kushlinskii, N., Loginov, V., & Braga, E. (2024). Methylation of Long Noncoding RNA Genes SNHG6, SNHG12, and TINCR in Ovarian Cancer. *Molecular Biology*. https://www.semanticscholar.org/paper/bd5705dfd02906786b3e4d29e16d5d23e257cdbe

[3] Wang, Q., Li, G., Ma, X., Liu, L., Liu, J., Yin, Y., Li, H., Chen, Y., Zhang, X., Zhang, L., Sun, L., Ai, J., & Xu, S. (2023). LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1–TINCR-USP20-PD-L1 axis. *Cell Death and Disease*. https://www.semanticscholar.org/paper/d1653694cd1d873d19702b630b89444c207c1ad7

[4] Morgado-Palacin, L., Brown, J. A., Martinez, T. F., García-Pedrero, J., Forouhar, F., Quinn, S. A., Reglero, C., Vaughan, J., Hajy Heydary, Y., Donaldson, C., Rodríguez-Perales, S., Allonca, E., Granda-Díaz, R., Fernández, A., Fraga, M., Kim, A., Santos-Juanes, J., Owens, D., Rodrigo, J., Saghatelian, A., & Ferrando, A. (2023). The TINCR ubiquitin-like microprotein is a tumor suppressor in squamous cell carcinoma. *Nature Communications*. https://www.semanticscholar.org/paper/f3f7277ea356c646d98b403d6892ac03391eeb2e

[5] Lukina, S., Burdennyy, A., Filippova, E., Uroshlev, L. A., Pronina, I., Ivanova, N. A., Fridman, M., Zhordania, K. I., Kazubskaya, T., Kushlinskii, N., Loginov, V., & Braga, E. (2024). Methylation of long non-coding rna genes: SNHG6, SNHG12, TINCR in ovarian cancer. *Molekulârnaâ biologiâ*. https://www.semanticscholar.org/paper/5e89580fe3ddb18526ce80be502d19766a869d6a

[6] Xu, J., Zeng, W., Liu, T., Wan, Z., Yang, X., Chen, J., & Liu, F. (2023). lncRNA TINCR knockdown inhibits colon cancer cells via regulation of autophagy. *Food Science & Nutrition*. https://www.semanticscholar.org/paper/4601174d109f4cc2801b54c4e2f1d7f1fa997eb4

[7] Shi, J., Guo, C., Li, Y., & Ma, J. (2022). The long noncoding RNA TINCR promotes self-renewal of human liver cancer stem cells through autophagy activation. *Cell Death and Disease*. https://www.semanticscholar.org/paper/97a04b2738c099edea71e43ded51c388ae987add

[8] Chen, L., Pan, L., Zhang, Y., Chen, Y., Su, Y., Luo, Y., Wu, Z., Zheng, W., Cai, S., Liu, X., & Wu, X. (2022). Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis.